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Preamble
The recent U.S. Food and Drug Administration (FDA)
“boxed warning” on clopidogrel raises important questions
for practitioners and patients. The warning addresses the
need for pharmacogenomic testing to identify patients’
altered clopidogrel metabolism and thus their risk for a
suboptimal clinical response to clopidogrel. Although there
is an expanding database on genetic polymorphisms that
may affect clopidogrel metabolism and thus clinical out-
comes, there are no evidence-based data upon which to
his document was approved by the American College of Cardiology Foundation
ACCF) Board of Trustees in June 2010, by the American Heart Association (AHA)
cience Advisory and Coordinating Committee in June 2010, as well as endorsed by
he Society for Cardiovascular Angiography and Interventions and the Society of
horacic Surgeons in June 2010.
The ACCF requests that this document be cited as follows: Holmes DR Jr., Dehmer
J, Kaul S, Leifer D, O’Gara PT, Stein CM. ACCF/AHA clopidogrel clinical alert:
pproaches to the FDA “Boxed Warning”: a report of the American College of
This article has been copublished in Circulation.
Copies: This document is available on the World Wide Web sites of the
American College of Cardiology (www.cardiosource.org) and the American Heart
Association (my.americanheart.org). For copies of this document, please contact
Elsevier Inc. Reprint Department, fax 212-633-3820, e-mail reprints@
elsevier.com.
Permissions: Multiple copies, modification, alteration, enhancement, and/or dis-
tribution of this document are not permitted without the express permission of theD
G
S
P
C
*llege of Cardiology Foundation. Please contact healthpermissions@
d
t
s
o
H
T
r
a
m
P
W
m
r
b
I
r
f
p
d
c
r
f
d
t
A
C
g
S
b
i
c
b
c
c
p
A
o
k
1
W
O
c
d
p
T
i
c
p
s
o
a
c
t
f
i
a
m
s
f
c
l
n
d
w
t
o
m
m
d
s
p
t
r
a
s
a
r
w
a
a
y
w
e
t
d
p
C
e
m
o
(
l
f
l
d
T
r
i
u
c
322 Holmes Jr. et al. JACC Vol. 56, No. 4, 2010
ACCF/AHA Clopidogrel Clinical Alert July 20, 2010:321–41evelop specific recommendations on the role of genetic
esting in routine care nor strategies proven to improve the
afety/efficacy of specific pharmacologic approaches.
To provide guidance on this issue, the American College
f Cardiology Foundation (ACCF) and the American
eart Association (AHA) convened a writing committee.
he ACCF and AHA adhere to a rigorous policy regarding
elationships with industry and other entities (RWI) of
uthors and peer reviewers for clinical document develop-
ent (see http://www.cardiosource.org/Science-And-Quality/
ractice-Guidelines-and-Quality-Standards/Relationships-
ith-Industry-Policy.aspx). This policy requires that a
ajority of writing committee members have no relevant
elationships with industry to this topic, a standard that has
een achieved for this document as indicated in Appendix 1.
n the spirit of full disclosure, comprehensive RWI (RWI not
elevant to this document) for all authors is available online
or public view. RWI restrictions are not applicable for
articipation in the external peer review process for clinical
ocuments in order to ensure that a variety of constituen-
ies/views inform the final document; however, all relevant
eviewer RWI is published in Appendix 2 for the purpose of
ull transparency. In addition, reviewer affiliation for this
ocument is recorded in Appendix 2, indicating participa-
ion of the following societies in the review process: the
merican Academy of Family Physicians, the American
ollege of Physicians, the Society for Cardiovascular An-
iography and Interventions, and the Society of Thoracic
urgeons. The ACCF and AHA believe this document will
e helpful during a time when information on this topic is
ncomplete and continually changing. For some of the
linical issues in this document, final published data may not
e available, in which case we have clearly identified this
oncern in the text. In addition to this document, an expert
onsensus document on the interaction of clopidogrel and
roton pump inhibitors is in progress by the ACCF,
merican College of Gastroenterology, and AHA. Our
rganizations remain committed to providing guidance on
ey clinical issues to promote optimal patient care.
Ralph G. Brindis, MD, MPH, FACC, FSCAI
President, American College of Cardiology Foundation
Clyde W. Yancy, MD, FACC, FAHA
President, American Heart Association
. Review of FDA Boxed Warning—
hat Did the FDA Say?
n March 12, 2010, the FDA approved a new label for
lopidogrel with a “boxed warning” (Appendix 3) about the
iminished effectiveness of the drug in patients with im-
aired ability to convert the drug into its active form (1).
his warning was the third FDA label change related to this
ssue in the last year. The boxed warning is based on the
oncern that the antiplatelet effect of clopidogrel depends mrimarily on its activation by the cytochrome P450 (CYP)
ystem. Patients with decreased CYP2C19 function because
f genetic polymorphisms metabolize clopidogrel poorly
nd have higher rates of cardiovascular events after acute
oronary syndrome (ACS) and percutaneous coronary in-
erventions (PCIs) than patients with normal CYP2C19
unction. The warning also notes that tests are available to
dentify patients with genetic polymorphisms, and that
lternative treatment strategies should be considered in poor
etabolizers of the drug.
The new label emphasizes a single study of 40 healthy
ubjects (10 each with different degrees of CYP2C19
unction—poor, intermediate, extensive, and ultrarapid) in a
rossover design. Each group was randomized to a 300-mg
oading dose (LD) followed by a 75-mg per day mainte-
ance dose (MD), or a 600-mg LD followed by 150-mg per
ay MD, each for a total of 5 days (Appendix 3). After a
ashout period, subjects were crossed over to the alternate
reatment. The chief findings were decreased active metab-
lite exposure and increased platelet aggregation in the poor
etabolizers compared with the other groups. When poor
etabolizers received the 600-mg LD followed by 150 mg
aily MD, active metabolite exposure and antiplatelet re-
ponse were greater than with the 300-mg LD and 75 mg
er day MD regimen, but remained quantitatively less than
he response in the extensive metabolizers when they
eceived the 300 mg and 75 mg regimen. Two different
ssays for platelet function were used—platelet aggregation
timulated by 5 micromolar adenosine diphosphate (ADP)
nd the vasodilator-stimulated phosphoprotein phopspho-
ylation assay. Improvement in platelet inhibitory responses
ith higher-dose clopidogrel in poor metabolizers was
pparent only with the former assay. There was no comment
bout statistical significance in the labeling material. Anal-
sis of the final as yet unpublished data set of this study,
hich played a prominent role in the boxed warning, will be
ssential to a more complete understanding of the issues.
To fully understand the new label, it is necessary to consider
he other background information upon which the label was
eveloped. There are 3 major CYP2C19 genetic polymor-
hisms. CYP2C19*1 corresponds to normal function.
YP2C19*2 and CYP2C19*3 are loss-of-function alleles and
xplain most of the reduced function in those who are “poor
etabolizers.” CYP2C19*2 and *3 account for 85% and 99%
f the nonfunctional alleles in whites and Asians, respectively
Appendix 3). Poor metabolizers have 2 loss-of-function al-
eles. Intermediate metabolizers have 1 copy of a loss-of-
unction allele and may also have decreased active metabolite
evels and reduced antiplatelet effects when treated with clopi-
ogrel, but the boxed warning only refers to poor metabolizers.
he new label alludes to multiple retrospective, prospective
andomized, and cohort clopidogrel studies that document
ncreased major adverse cardiac event (MACE) rates in pop-
lations with genetic polymorphisms. Several cohort studies
ited in prior FDA versions of the label and referred to in the
ost recent label have also shown variations in event rates that
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July 20, 2010:321–41 ACCF/AHA Clopidogrel Clinical Alertepend on CYP2C19 genotype (2–4). As the new label notes,
ests are now available to determine CYP2C19 genotypes for
linical purposes.
Conversely, it is also important to note what the label
oes not say. When the first of the label revisions was being
eveloped in early 2009, the FDA proposed a recommen-
ation for genotyping to identify patients with impaired
YP2C19 function and a comment stating that higher
oses may be considered in these patients. After discussion
ith the manufacturer, however, no recommendation for
enotyping was included in the label at that time. Instead,
he initial 2009 revision (dated May 5, 2009) simply noted
hat “poor metabolizer status is associated with diminished
esponse to clopidogrel” and that “the optimal dose for poor
etabolizers has yet to be determined” (5). The second
evision in 2009 advised avoiding the use of clopidogrel “in
atients with impaired CYP2C19 function due to known
enetic polymorphisms or due to drugs that inhibit
YP2C19 activity” and added additional information about
he interaction of clopidogrel and omeprazole (6). The most
ecent revision, in March 2010, no longer specifically advises
voidance of clopidogrel in patients with known genetic
olymorphisms of CYP2C19 but rather states that physi-
ians should “consider alternative treatment or treatment
trategies in patients identified as CYP2C19 poor metabo-
izers” (1). In addition, it should be noted that although it is
ssumed that it is the influence of the genotype on the
henotype of platelet reactivity that causes the increased rate
f adverse clinical events, it remains possible that there may
e other independent adverse effects of the genotype.
In the current warning, the moderate position of the
DA does not appear merely to be a reluctance to make
trong recommendations about genetic testing, but rather to
eflect an attempt to weigh the evidence and to give the
rescriber more information. The FDA has made recom-
endations of different strengths related to genetic varia-
ions on multiple occasions (7) in recent years with some
oxed warnings like those for carbamazepine and abacavir
hat explicitly recommend genetic testing and advise against
enerally treating patients with certain genotypes with these
rugs (8,9). In contrast, the FDA-approved label for war-
arin mentions information about allelic variants that alter
atient responsiveness to it, but does not include a “boxed
arning” about this (10).
.1. Background and Significance of
oxed Warnings and How These Relate
o the Clopidogrel Warning
t is important to understand when the FDA requires such
warning. The Code of Federal Regulations (10a) requires
hat “labeling shall be revised to include a warning as soon
s there is reasonable evidence of an association of a serious
azard with a drug; a causal relationship need not have been
roved. Special problems, particularly those that may lead to
eath or serious injury, may be required by the [FDA] to be 1laced in a prominently displayed box. The ‘boxed warning’
rdinarily shall be based on clinical data” (11).
The FDA leaves decisions about what to do with the
nformation in boxed warnings up to individual clinicians
11). It does not necessarily recommend a particular plan for
ow to deal with the information. It has been emphasized
hat the intent of information that the FDA puts into such
warning is to share the data with prescribers so they can be
nformed and make decisions based on patient-specific
actors. The decision to perform CYP2C19 genetic testing
s best made by the prescriber of the medication and the
nformed patient.
In brief, the clopidogrel boxed warning leaves the issue of
hether to perform CYP2C19 testing up to the individual
hysician. It does not specifically require genetic testing or
ther changes in evaluation or treatment and does not imply
hat there are solid evidence-based reasons for such actions.
ather, it serves to make clinicians aware of the imperfect,
ut significant, knowledge that we have about genetic
ariations in response to clopidogrel and to emphasize that
linicians should use this knowledge to make decisions
bout how to treat individual patients.
. Evidence on Variability to
lopidogrel Response
lopidogrel, a thienopyridine P2Y12 ADP receptor antagonist,
equires bioactivation to its active metabolite (R130964) to
nhibit platelet aggregation. There is substantial individual
ariability in response to clopidogrel, with inhibition of ADP-
nduced platelet aggregation ranging from less than 10% to
lmost complete inhibition of platelet aggregation with a wide
istribution across this range, such that there is no dichoto-
ous separation into “responders” and “nonresponders” (12).
evertheless, a meta-analysis and other data suggest that
esidual platelet reactivity in patients receiving clopidogrel is
ssociated with an increased risk of cardiac, cerebrovascular,
nd peripheral arterial events (12–14). This variability may be
ue to pharmacokinetic (PK) or pharmacodynamic (PD)
actors (i.e., differences respectively in either kinetics/
oncentration of the active metabolite or in the response of
latelets). The variability in clopidogrel PK and PD is due to
everal factors: demographic variables such as increased age and
ody mass index, comorbidities such as diabetes and dyslipi-
emia, and other factors that remain to be identified (15).
lthough genetic variability also plays an important role in
DP-stimulated platelet aggregation in response to clopi-
ogrel, known genetic and nongenetic factors explain only a
ortion of the majority of variation (15).
.1. Genetic Variability and Clopidogrel Response
.1.1. CYP2C19 Variants
YP2C19 plays an important role in the bioactivation of
lopidogrel, a prodrug. Once absorbed, only approximately
5% of clopidogrel is bioactivated in the liver in a 2-step
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ACCF/AHA Clopidogrel Clinical Alert July 20, 2010:321–41rocess that is mediated by several CYP450 isoenzymes
Figure 1) (16). Of these, CYP2C19 is responsible for
pproximately 45% of the first step (the formation of
-oxo-clopidogrel) and approximately 20% of the final
tep—the generation of the pharmacologically active thiol
etabolite. There are genetic polymorphisms in several
YP450 enzymes involved in the metabolism of clopi-
ogrel, but variants in CYP2C19, particularly CYP2C19*2,
re reproducibly associated with variability in clopidogrel
ctive metabolite bioavailability, antiplatelet effects, and
linical outcomes (2,15,17). The CYP2C19*2 variant en-
odes a nonfunctional protein. There are ethnic differences
n its distribution; approximately 50% of Chinese, 34% of
frican Americans, 25% of Whites, and 19% of Mexican
mericans carry at least 1 copy of the reduced function
YP2C19*2 allele (18,19). Other genetic polymorphisms
ssociated with impaired CYP2C19 activity and possibly
dverse clinical events (CYP2C19*3, *4, *5, *8) are much
ess common in Whites, African Americans, and Hispanics
18). In the randomized control TRITON–TIMI 38 (Trial
o Assess Improvement in Therapeutic Outcomes by Op-
imizing Platelet Inhibition With Prasugrel–Thrombolysis
n Myocardial Infarction 38), comparing clopidogrel with
rasugrel in patients with ACS, CYP2C19*2 accounted for
5% of the subjects classified as carriers of a reduced
YP2C19 function allele (17). The number of reduced
unction alleles is important: individuals with 1 variant allele
intermediate metabolizers) had 26% to 31% lower exposure
o the active metabolite of clopidogrel, and those with 2
enetic polymorphisms (poor metabolizers) had 46% to 55%
ower exposure compared with those with no CYP2C19
olymorphisms (17).
The effect of variant CYP2C19 alleles on clinical out-
igure 1. Schematic Representation of the Metabolism of Clopido
eprinted with permission from Mega et al. (16).ome in response to clopidogrel has been reported in Cultiple studies (Table 1) (20,21). All of these were cohort
tudies, with 1 being a genetic substudy derived from
RITON–TIMI 38. A significant association between the
YP2C19*2 polymorphism and an increased risk of major
dverse cardiovascular events was reported in 5 of 7 studies.
he risk ranged from a 53% relative increase in TRITON–
IMI 38 (17) to an approximately 5-fold increase in a
ohort study of young patients treated with clopidogrel after
cute myocardial infarction (MI) (2). In the latter study,
fter multivariable analysis, CYP2C19*2 was the only factor
ndependently associated with new cardiovascular events
hazard ratio [HR] 4.04 [95% confidence interval (CI) 1.81
o 9.02]; p0.0006) (2). However, because none of the
tudies were randomized, the possibility of bias and con-
ounding variables cannot be excluded. For example, pa-
ients who had an event were more likely to be receiving
lopidogrel at baseline in some studies. Thus, a group of
lopidogrel nonresponders may have been preselected and
verrepresented in some studies. In addition, the scope of
he genetic problem is not isolated to patients with 2
eficient alleles (homozygotes). This has important impli-
ations because of the higher prevalence of heterozygotes in
he population. The data on positive and predictive risk in
pecific patient populations are incomplete (22). Thus,
aution must be observed in drawing definitive conclusions
rom these observational studies.
These clinical efficacy data mirror the effect of genetic
olymorphisms on platelet function in both heterozygotes
s well as homozygotes. Carriers of a CYP2C19*2 allele
ave been found to have an absolute reduction in platelet
ggregation in response to clopidogrel that was 9 percentage
oints less than that of noncarriers (17). Other studies (23)
ave noted that carriers of at least 1 reduced function
nd Prasugrelgrel aYP2C19 allele have less response to clopidogrel reflected
Table 1. CYP2C19*2 Polymorphisms and Cardiovascular Outcomes
Source, Year
(Region)
Patients, n
(Age, Years) Disease Clopidogrel Dosage
Duration of
Follow-Up
(Months) Outcome (n)
Frequency of Genotype, n (%)
RR (95% CI) Adjustment*1/*1 *1/*2 *2/*2
Trenk et al., 2008
(Germany) (21)
797
(mean: 66.4)
CAD LD 600 mg
MD 75 mg day1
12 Death and MI (24) 552 (69.3) 228 (28.6) 17 (2.1) 0.67 (0.25–1.78)† None
Simon et al., 2009
(France) (22)
2178
(mean: 70.1)
AMI LD 300 mg
MD 75 mg day1
12 Death from any cause
(225)
1561 (71.7) 564 (25.9) 53 (2.4) 0.89 (0.68–1.18)† None
Collet et al., 2009
(France) (2)
259
(18–45)
MI LD n.d.
MD 75 mg day1
100 Death, MI,
urgent coronary
revascularization (26)
Stent thrombosis (12)
186 (71.8) 73 (28.2) 5.38 (2.32–12.47)
6.04 (1.75–20.80)
BMI smoking,
diabetes, stent
implantation, STEMI,
use of proton-pump
inhibitors
Mega et al., 2009
(United States) (17)
1459
(mean: 60.1)
ACS LD 300 mg
MD 75 mg day1
15 Death from CV causes,
MI, stroke (129)
Stent thrombosis (18)
1064 (72.9) 395 (27.1) 1.53 (1.07–2.19)
3.09 (1.19–8.00)
None
Sibbing et al., 2009
(Germany) (4)
2485
(mean: 66.5)
CAD LD 600 mg
MD 75 mg day1
1 Stent thrombosis (17) 1805 (73) 633 (25) 47 (2) 3.81 (1.45–10.02) Age, diabetes, ACS,
type of stent
Giusti et al., 2009
(Italy) (3)
772
(mean: 68.3)
ACS LD 600 mg
MD 75 mg day1
6 Stent thrombosis 
cardiac mortality (29)
Stent thrombosis (24)
525 (68) 221 (28.6) 26 (3.4) 2.70 (1.00–8.42)
3.43 (1.01–12.78)
Residual platelet
reactivity, traditional
CV risk factors,
clinical and
procedural risk
factors
Shuldiner et al., 2009
(United States) (15)
93‡
(mean: 65)
CAD LD 300/600 mg day1
MD 75 mg day1
12 MI, unplanned target
and nontarget lesion
revascularization,
hospitalization, death
from CV causes
(n not reported)
66 (70.9) 27 (29.1) 3.40 (1.36–8.46) Age, gender, race
Reprinted with permission from Sofi et al. (20). †Calculated from data taken from the original text; ‡only patients who were still taking clopidogrel after 1 year.
ACS indicates acute coronary syndromes; AMI, acute myocardial infarction; BMI, body mass index; CAD, coronary artery disease; CI, confidence interval; CV, cardiovascular; LD, loading dose; MD, maintenance dose; MI, myocardial infarction; n.d., no date; RR, risk
ratio; and STEMI, ST-segment elevation myocardial infarction.
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ACCF/AHA Clopidogrel Clinical Alert July 20, 2010:321–41s a higher residual platelet reactivity index. In a genome-
ide association study performed in a homogenous popu-
ation of healthy Amish—PAPI (Pharmacogenomics of
ntiplatelet Intervention)— clopidogrel reduced ADP-
nduced platelet aggregation to 41%, 47%, and 65% of
aseline in subjects with 0, 1, and 2 CYP2C19*2 alleles,
espectively (15), thereby exhibiting a gene-dose effect.
owever, even in this relatively homogenous population,
YP2C19*2 genotype accounted for only 12% of the
ariability in clopidogrel response (15).
In contrast to clopidogrel, the FDA-approved drug,
rasugrel, is oxidized to its active form in a single CYP-
ependent step (Figure 1). In 238 healthy subjects tested,
here was no significant decrease in the plasma concentra-
ions of active metabolite or platelet inhibition in response
o prasugrel in carriers versus noncarriers of at least 1
educed function allele for the CYP genes tested (2C19,
C9, 2B6, 3A5, 1A2) (16). Similar observations were
eported in patients with stable coronary artery disease (23).
he association of these genetic variants with cardiovascular
utcomes was examined in 1466 patients with ACS allo-
ated prasugrel in TRITON-TIMI 38. No significant
ssociations were found between any of the CYP genes
ested and risk of cardiovascular death, MI, or stroke (16).
icagrelor, which is not yet approved, is a reversible,
onthienopyridine P2Y12 receptor antagonist; it is not a
rodrug, and does not require biotransformation (24,25).
he effect of genetic polymorphisms in CYP isoenzyme
unction or number for this drug remains incompletely
efined. Other drugs, such as elinogrel (not yet approved),
ave also been studied (26).
.1.2. Other Genetic Polymorphisms
ther genetic variations may also affect the PK, PD, and
linical efficacy of clopidogrel (27).
.1.2.1. ABCB1
ntestinal absorption is limited by the P-glycoprotein efflux-
ransporter encoded by the adenosine triphosphate-binding
assette containing gene ABCB1, also known as the mul-
idrug resistant (MDR1) gene. Compared with noncarriers
wild-type or CC genotype), the bioavailability of clopi-
ogrel is significantly reduced among patients receiving a
00- or 600-mg LD before elective PCI who have either 1
CT genotype) or 2 (TT genotype) copies of the ABCB1
3435T single nucleotide polymorphism (28). In acute MI
atients, the frequency of the variant TT genotype (TT
6%, CC 26%, CT 48%) was significantly higher among the
94 patients with an outcome event (death, nonfatal MI, or
troke at 1 year) compared with the 1914 patients without
n event (29% versus 26%, p0.04). In addition, patients
ith the TT genotype had significantly higher event rates at
year than those with the ABCB1 wild-type (CC) geno-
ype (15.5% versus 10.7%; adjusted HR 1.72; 95% CI 1.20
o 2.47) (22). Patients who possessed 2 CYP2C19 loss-of-
unction alleles and at least 1 ABCB1 variant allele were at she highest risk for a primary outcome event (HR 5.31; 95%
I 2.13 to 13.20) compared with patients who had both
YP2C19 and ABCB1 (22). In another study of 2934 ACS
atients, TT homozygotes had a 72% increased risk of the
omposite primary end point (cardiovascular death, MI, or
troke at 15 months) compared with either CC or CT
atients (HR 1.72, p0.002) (29). Additional information
n the frequency and consequences of combined, function-
lly important genetic polymorphisms is required.
.1.2.2. OTHER CYP ISOENZYMES
he CYP3A4 and CYP3A5 enzymes also play a role in the
onversion of clopidogrel to its active metabolite. In a substudy
f healthy volunteers analyzed along with TRITON–TIMI
8, carrier status for a reduced function allele of CYP2C9,
A5, and 1A2 was not associated with a consistent reduction of
he PK or PD responses to clopidogrel. Carriers of a reduced
unction CYP2B6 allele, however, tended to have a lower
lasma exposure to the active metabolite of clopidogrel and
ended to have less reduction of platelet aggregation in re-
ponse to clopidogrel (16,17). One other study reported that
ubjects with the CYP3A5*3 allele had significantly decreased
esponse to clopidogrel when it was combined with itracon-
zole, a CYP3A inhibitor, compared with CYP3A5*1 ho-
ozygotes (30).
.1.2.3. P2Y12 RECEPTOR
tudies have also assessed genetic variation in the gene
ncoding the P2Y12 receptor (the binding site for clopi-
ogrel metabolite). In the FAST-MI (Registry on Acute
T–Elevation Myocardial Infarction) study, no association
as found with clopidogrel responsiveness and the genetic
olymorphism encoding the P2Y12 receptor (22). Other
tudies have also yielded similar results (31).
. Current Status of
YP2C19 Genotyping Assays
iven the increasing importance of genetic variations, there
as been increasing interest in genetic testing to identify
ptimal strategies of care. This feature is a central compo-
ent of the new clopidogrel boxed warning. Commercial
ssays are available from both research and clinical labora-
ories. Cross validation of the techniques used and their
eliability, specificity, and reproducibility are extremely lim-
ted. While results of commercial assays can be applied, they
re not available in the acute phases of patient care. Point-of-
are assays for the common CYP2C19 polymorphisms are
ot available at this time. In addition, genetic polymor-
hisms with gain-of-function (CYP2C19*17), and uncom-
on alleles with reduced function (e.g., CYP2C19*3, *4, *5)
ay affect clinical outcomes. An important patient care
ssue relates to the cost for these tests (approximately $500),
hich are typically not reimbursed by major payers. Alter-
atives to genetic testing focus on the phenotype—
pecifically, platelet function. Platelet function assays can
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July 20, 2010:321–41 ACCF/AHA Clopidogrel Clinical Alerteasure the effect of ADP or P2Y12 activation on platelet
ggregation, receptor expression, or the level of intracellular
olecules (e.g., vasodilator-stimulated phosphoprotein
hopsphorylation), thereby directly or indirectly measuring
he platelet inhibitory effect of clopidogrel (i.e., clopidogrel
esponsiveness or on-treatment reactivity). Additional clin-
cal studies are underway to test whether altering therapy in
esponse to residual high platelet reactivity after clopidogrel
dministration is associated with improved clinical out-
omes.
. Alternative Dosing Regimens
or Clopidogrel
valuation of the different strategies developed and tested to
vercome clopidogrel nonresponsiveness must consider the
ype of study, patient population, metrics of evaluation, and
uration of follow-up. Each of these variables may affect
nterpretation of these data and the application of a specific
herapeutic approach to an individual patient. There are few
ata on the inhibitory effect of alternative dosing regimens
n CYP2C19 intermediate and/or poor metabolizers.
Several studies have evaluated the effect of different
ombinations of clopidogrel LDs and MDs on platelet
able 2. Pharmacodynamic Studies of Platelet Responsiveness
Study Regimen
SAR-CHOICE (33)
60 elective PCI patients; C-naïve
C, 300, 600, 900 mg LD
on Beckerath et al. (34)
60 patients after successful PCI; 600 mg C load
C, 150 mg daily vs.
75 mg daily (MD)
PTIMUS study (35)
40 patients with type 2 DM and documented
suboptimal response to C
C, 150 mg daily vs.
75 mg daily (MD)
ontana et al. (36)
81 patients with recent PCI and documented
suboptimal platelet inhibition on C 75 mg daily
C increased to 150 mg
daily C (MD)
RINC trial (37)
60 patients undergoing PCI; C, 600 mg LD
2 h after initial C-load,
either 600 mg C
or placebo, then
second randomization
to 150 mg C vs.
75 mg C daily
ASP-02 (38)
153 patients undergoing elective PCI
C, 150 mg versus 75 mg
daily for 4 wk; after 2
platelet inhibition
checked and low
responders increased
150 mg daily
rice et al. (40)
45 volunteers
C, 300, 600, 900 mg LD
ontalescot et al. (ALBION) (41)
103 patients with NSTEMI
C, 300, 600, 900 mg LD
DP indicates adenosine diphosphate; ALBION, Assessment of the Best Loading Dose of Clop
ellitus; IPA, inhibition of platelet aggregation; ISAR-CHOICE, Intracoronary Stenting and Antithr
ose; MD, maintenance dose; NSTEMI, non–ST-segment elevation myocardial infarction; OPTIMU
lavix Response in Coronary Intervention; and VASP-02, Vasodilator-Stimulated Phosphoproteinggregation, metabolites of clopidogrel, and other measures if platelet function (32–41) (Table 2). Some studies were
erformed specifically in patients with a documented sub-
ptimal response to the usual dosing protocols for clopi-
ogrel (35,36,38). However, there are less data on the effect
f alternative dosing regimens in intermediate and/or poor
etabolizers and a lack of data supporting a change in
herapy based on genotyping alone. In general, a 600-mg
D or double LD (second 600-mg dose 2 hours later)
mproves the degree of acute platelet inhibition (33,37).
oreover, an MD of 150 mg daily results in a greater
egree of platelet inhibition in many studies in patients with
reduced response to the usual 75-mg MD (36–38).
owever, even at the higher dose, some patients do not
each an optimal level of platelet inhibition ex vivo (35).
Fewer studies have examined patient outcomes after differ-
nt clopidogrel dosing protocols including an additional
00-mg LD at the time of PCI in patients already receiving 75
g daily (40), 600-mg versus 300-mg LD in patients with
T-segment elevation MI undergoing primary PCI (41), and
00-mg LD followed by 150 mg daily for 1 week in patients
ith ACS (41a) (Table 3). There was no overall benefit of
eloading clopidogrel prior to PCI in patients already receiving
hronic clopidogrel in the ARMYDA-4 RELOAD (Anti-
latelet Therapy for Reduction of MYocardial Damage Dur-
ifferent Clopidogrel Dosing Protocols
Metric Results
Platelet aggregometry,
active thiol
metabolite of C
600 mg dose had highest active drug metabolite
level and platelet suppression compared with
the 300 mg dose.
30-d platelet function C, 150 mg daily had more intense platelet
inhibition.
Repeat platelet
function testing
after 30 d
150 mg dose improved rates of platelet inhibition,
but 60% of patients still had suboptimal C
effect.
Repeat platelet
function testing
after 15 d
C, 150 mg daily improved platelet inhibition.
Platelet inhibition at
2, 4, and 7 h, and
1 wk
600 mg load  2 at 2 h apart produced better
inhibition than 600 mg acutely;
150 mg daily results in better inhibition than
75 mg after 1 wk.
Platelet inhibition at
2 and 4 wk
At 2 wk, 150 mg C produced better platelet
inhibition.
In low responders, 150 mg C improved platelet
inhibition.
Platelet inhibition at
baseline and
1 through 7 h
600 mg and 900 mg had more intense platelet
inhibition than 300 mg, no difference between
600 mg and 900 mg.
ADP-induced IPA at
24 h
LDs greater than 300 mg provided greater
antiplatelet effect than 300 mg
to Blunt Platelet Activation, Inflammation and Ongoing Necrosis; C, clopidogrel; DM, diabetes
Regimen: Choose Between 3 Higher Oral Doses for Immediate Clopidogrel Effect; LD, loading
izing Antiplatelet Therapy in Diabetes Mellitus; PCI, percutaneous coronary intervention; PRINC,
domized Study.to D
wk,
to
idogrel
omboticng Angioplasty-4 RELOAD) study, although patients with
A
t
c
H
l
6
M
O
O
w
c
u
w
d
n
g
h
c
d
i
t
r
c
v
p
p
a
r
c
M
t
p
p
d
c
A
m
(
o
p
r
i
a
b
p
w
g
a
H
e
p
r
h
t
f
d
o
m
h
M
d
f
E
m
s
t
w
h
l
b
7
T
A
H
C
*
C
R ents; M
S
328 Holmes Jr. et al. JACC Vol. 56, No. 4, 2010
ACCF/AHA Clopidogrel Clinical Alert July 20, 2010:321–41CS did appear to do better with the extra LD (42). Because
he overall study was negative, the results obtained in the ACS
ohort should be considered hypothesis-generating only. In the
ORIZONS-AMI (Harmonizing Outcomes With Revascu-
arization and Stents in Acute Myocardial Infarction) trial, a
00-mg dose was an independent predictor of lower 30-day
ACE (43). In the CURRENT–OASIS-7 (Clopidogrel
ptimal Loading Dose Usage to Reduce Recurrent Events–
ptimal Antiplatelet Strategy for Interventions-7) trial, there
as no increase in efficacy of double-dose versus standard-dose
lopidogrel in the overall cohort (41a). However, in patients
ndergoing PCI (nearly 75% of the overall cohort), MACE
as significantly reduced but bleeding was also increased with
ouble-dose clopidogrel (41a). Because the overall study was
egative, the results obtained in this postrandomization sub-
roup of patients undergoing PCI should be considered
ypothesis-generating only.
Other strategies have been tested to overcome deficits in
lopidogrel responsiveness. One approach is to add a third
rug to aspirin and clopidogrel to further enhance platelet
nhibition. Cilostazol acts via a different pathway to selec-
ively inhibit phosphodiesterase type 3 and affects adenosine
euptake and nitric oxide PGI2 production by endothelial
ells (44). It is approved for use in patients with peripheral
ascular disease and claudication; thus, its use to enhance
latelet inhibition in PCI patients is off-label. After stent
lacement, patients with persistently high platelet reactivity
fter a 300-mg LD of clopidogrel were randomized to
eceive either high-dose clopidogrel (150 mg daily) or
ilostazol (100 mg twice daily) with the standard clopidogrel
D (45). Adjunctive cilostazol intensified platelet inhibi-
ion to a greater degree than high-dose clopidogrel in these
atients and also in a separate study of patients undergoing
rimary PCI for ST-segment elevation MI (46). However,
ata on the effect of adjunctive cilostazol on clinical out-
omes are conflicting. In a study of Asian patients with
able 3. Effect of Different Clopidogrel Dosing Protocols on Pa
Study Regimen
RMYDA-4 RELOAD (42)*
503 stable AP or non-STEMI ACS
patients on chronic C for more
than 10 d
600 mg load vs. placebo 3
ORIZONS-AMI (43)
3602 STEMI patients
600 mg vs. 300 mg C load 3
URRENT OASIS-7*
25,098 ACS patients (41a)
High-dose C  600-mg loading
dose, then 150 mg for 7 d,
then 75 mg daily to 30 d;
standard dose C  300 mg
loading dose, then 75 mg
daily to 30 d
3
Because the overall study was negative, the results obtained in the ACS subgroup in ARMYDA
ACS indicates acute coronary syndromes; AP, angina pectoris; ARMYDA-4 RELOAD, Antiplat
URRENT OASIS-7, Clopidogrel Optimal Loading Dose Usage to Reduce Recurrent Events/
evascularization and Stents in Acute Myocardial Infarction trial; MACE, major adverse cardiac ev
T-segment elevation myocardial infarction; and TVR, target-vessel revascularization.CS, adjunctive cilostazol improved clinical outcomes at 6 aonths, but no platelet function testing was performed
47). However, in the recently reported CILON-T (Efficacy
f Cilostazol on Ischemic Complications After DES Im-
lantation) study, adjunctive cilostazol did not result in a
eduction in cardiovascular events at 6 months despite
mproved platelet inhibition (47a). In addition, drug inter-
ctions and gastrointestinal intolerance with cilostazol may
e problematic. Other isolated studies show enhanced
latelet inhibition or a reduction in cardiovascular events
ith the addition of omega-3 fatty acids (48) or specific
lycoprotein IIb/IIIa inhibitors (abciximab and tirofiban)
dministered acutely with aspirin and clopidogrel (49,50).
owever, none of these studies provide substantial proof of
fficacy in large populations at risk.
The other approach has been to substitute a newer, more
otent platelet inhibitor drug for clopidogrel. Prasugrel,
ecently approved for clinical use, still requires single-step
epatic conversion to an active metabolite before binding to
he platelet P2Y12 receptor. It thus far appears to have very
ew poor responders in patients with stable coronary artery
isease (51) and in patients with ACS (52). Standard dosing
f prasugrel (60 mg loading, 10 mg daily) is associated with
ore potent platelet inhibition than clopidogrel even at
igh doses (600 mg loading, 150 mg daily) (51,53–55).
oreover, when administered chronically, a 10-mg daily
ose of prasugrel provides better inhibition of platelet
unction than 75 mg or 150 mg of clopidogrel daily.
nhanced platelet inhibition with prasugrel was docu-
ented in a small substudy of TRITON–TIMI 38 (52);
ignificantly reduced rates of ischemic events compared with
hose seen with clopidogrel, including stent thrombosis,
ere reported in TRITON–TIMI 38 (56). There was,
owever, an increased rate of major bleeding, including
ife-threatening bleeding. The 3 groups at highest risk for
leeding in TRITON–TIMI 38 included those greater than
5 years of age, with body weight less than 60 kg, and with
Outcomes
Metric Results
CE defined as cardiac death,
r TVR
No benefit in overall cohort. In non-STEMI
ACS patients, 600 mg load reduced
MACE (16.3% to 6.4%); no change in
MACE in stable AP.
CE defined as all-cause death,
e, reinfarction, unplanned
cularization for ischemia, or
r bleeding
600-mg dose was an independent
predictor of lower 30-d MACE
CE defined as cardiovascular
, MI, or stroke
No benefit in overall cohort. In subgroup
of 17,232 PCI patients, 15% reduction
in MACE in high-dose group with a
42% reduction in definite ST, but
increased bleeding
OAD and PCI subgroup in CURRENT OASIS-7 should be considered hypothesis-generating only.
erapy for Reduction of MYocardial Damage During Angioplasty-4 RELOAD trial; C, clopidogrel;
l Antiplatelet Strategy for Interventions trial; HORIZONS-AMI, Harmonizing Outcomes With
I, myocardial infarction; PCI, percutaneous coronary intervention; ST, stent thrombosis; STEMI,tient
0-d MA
MI, o
0-d MA
strok
revas
majo
0-d MA
death
-4 REL
elet Th
Optimahistory of stroke or transient ischemic attack. Prasugrel should
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July 20, 2010:321–41 ACCF/AHA Clopidogrel Clinical Alertot be used in patients with qualifying ischemic stroke. In an
ttempt to balance the excess risk of bleeding associated with
rasugrel with its benefit in reducing stent thrombosis (partic-
larly early after stent placement), some clinicians have used an
mpiric strategy of prasugrel for 1 month then followed by a
witch to a standard-dose clopidogrel.
Ticagrelor, although not yet available for clinical use, is an
ral, reversible P2Y12 receptor antagonist that blocks ADP-
nduced platelet aggregation and does not require metabolic
ctivation (24). Compared with clopidogrel in a large trial of
atients with ACS, ticagrelor significantly reduced the rate of
he primary composite end point of death from vascular causes,
I, or stroke (25). Ticagrelor reduced the individual compo-
ents of death from vascular causes and MI, but not the rate of
troke. While there was no increase in the rate of overall major
leeding, there was an increase in the rate of nonprocedure-
elated bleeding. Specifically in patients with a planned invasive
trategy, ticagrelor had significant and clinically relevant reduc-
ions in cardiovascular and total deaths, MI, and stent throm-
osis, without an increase in risk of major bleeding (57).
his drug has also been found to be effective in improving
latelet inhibition in patients who are nonresponders to
lopidogrel (58).
. Review of Ongoing Trials
esting for genetic polymorphisms received considerable
mphasis in the boxed warning. While CYP2C19 genetic
olymorphisms have been shown in several studies to reduce
lopidogrel metabolism and its PD effect and clinical
ffectiveness, there are no prospective studies demonstrating
clinical benefit to personalizing antiplatelet therapy based
n genotype analysis. The study upon which the FDA
ssued the boxed warning and based its statement “to
onsider alternative treatment strategies” is a small unpub-
ished crossover trial that evaluated PK and antiplatelet
esponses to clopidogrel in 40 healthy subjects. How these
ata should translate into clinical practice remains the focus
f ongoing studies. Several studies of different populations,
izes, degree of methodological rigor, and follow-up are
urrently underway or being planned to evaluate the role of
harmacogenetic (CYP2C19) profiling of patients in their
K (active metabolite exposure) and PD (platelet function
ssays) responses to clopidogrel (Table 4). Two of these
ngoing studies are exploring the influence of CYP2C19 in
he drug interaction between clopidogrel and proton pump
nhibitors, 1 with coadministration of statins (the SPICE
Evaluation of the Influence of Statins and Proton Pump
nhibitors on Clopidogrel Antiplatelet Effects] trial) and 1
ithout (the Influence of CYP2C19 Genetic Variants on
lopidogrel in Healthy Subjects study [NCT00413608]).
hree trials are evaluating the role of triple antiplatelet
herapy with cilastozol plus aspirin and standard dose
lopidogrel versus aspirin plus high-dose clopidogrel in
YP2C19-genotyped patients with stable and ACS dACCEL-2C19 [Adjunctive Cilostazol Versus High
aintenance-dose Clopidogrel According to Cytochrome
C19 Polymorphism] [NCT01012193], ACCELAMI2C19
Adjunctive Cilostazol Versus High Maintenance-dose Clo-
idogrel in Acute Myocardial Infarction (AMI) Patients Ac-
ording to CYP2C19 Polymorphism] [NCT00915733],
nd ACCEL2C19 [Comparison of Platelet Inhibition
ith Adjunctive Cilostazol Versus High Maintenance-
ose Clopidogrel According to Hepatic Cytochrome 2C19
llele (CYP2C19) Polymorphism] [NCT00891670] trials).
owever, use of a surrogate end point (ex vivo platelet
unction assays) in these trials may limit the clinical signif-
cance of these data, as the causal relationship between
aboratory measures of platelet function, and clinically
elevant cardiovascular end points remains unproven. In
ddition, it is unknown whether platelet function tests are
omplementary to genotyping. Only 1 large observational,
pen-label study is examining genotype-guided comparison
f clopidogrel 75 mg daily in extensive metabolizers
CYP2C19*1/*1) and prasugrel 5 mg or 10 mg daily
without complementary point-of-care testing of platelet
unction) on cardiovascular outcomes in patients with ACS
GeCCO [Genotype Guided Comparison of Clopidogrel
nd Prasugrel Outcomes Study] [NCT00995514]). Finally,
prospective randomized study—the PAPI-2 (Pharmacog-
nomics of Antiplatelet Intervention-2) trial—examining
he role of CYP2C19*2 variant in influencing the PK, PD,
nd clinical response to clopidogrel is planned to be launched
n the near future (A. Shuldiner, personal communication,
pril 2010). Whether the promise of pharmacogenetic testing
n tailoring antiplatelet therapy to the individual patient will be
ulfilled awaits the completion of these studies.
Platelet function testing used to tailor antiplatelet therapy
as also received considerable interest. Although this field
uffers from a surfeit of specific assays, definitions, and
rotocols, it has the advantage that point-of-care testing is
urrently available. There are currently 4 ongoing trials
esting the hypothesis that tailoring antiplatelet therapy
ased on platelet responsiveness assessed in an ex vivo P2Y12
ssay will improve cardiovascular outcomes. The details of
hese trials are summarized in Table 5. Patients with high
esidual platelet activity are randomly allocated to standard-
ose versus high-dose clopidogrel in 2 trials (GRAVITAS
Gauging Responsiveness With A VerifyNow Assay-Impact
n Thrombosis And Safety] and DANTE [Dual Antiplatelet
herapy Tailored on the Extent of Platelet Inhibition]), and to
tandard-dose clopidogrel versus prasugrel in 1 trial
TRIGGER-PCI [Testing Platelet Reactivity In Patients
ndergoing Elective Stent Placement on Clopidogrel to
uide Alternative Therapy With Prasugrel]), while the
RCTIC Double Randomization of a (Monitoring Adjusted
ntiplatelet Treatment Versus a Common Antiplatelet Treat-
ent for DES Implantation, and Interruption Versus Contin-
ation of Double Antiplatelet Therapy) trial is evaluating dose
djustment of dual antiplatelet therapy with aspirin and clopi-
ogrel on the basis of biological monitoring compared with the
TG
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Study Design
No. of
Patients Population Selection Criterion Outcome Follow-Up
Trials Evaluating Pharmacodynamic and/or Pharmacokinetic Outcomes
IFT
(NCT00992420)
PI: M.J. Price
Observational, prospective
cohort study (GRAVITAS
substudy)
(PD study)
Up to 2000 Stable CAD or
NSTEMI ACS
undergoing DES
Patients with high residual
platelet activity (HRPA) 12- to
24-h post-DES randomized to:
1) standard 75 mg
clopidogrel, or 2) high-dose
clopidogrel (additional 600
mg followed by 150 mg daily)
Association of CYP2C19
genotype with RPA
(VerifyNow) on
standard dose of
clopidogrel or
incremental change
RPA on high-dose
clopidogrel
6 mo
lopidogrel
Pharmacogenomics
Project
(NCT01097343)
PI: J. Dharmavaram
PI: J.S. Rossi
Randomized, open-label,
crossover, phase 0
(PD/PK study)
200 Stable CAD Screen for CYP2C19*2 LOF
allele; randomize eligible
patients to clopidogrel 75 mg
or 150 mg daily  30 d and
then crossover
Change in RPA
(VerifyNow, optical
aggregometry);
measurement of
active metabolites
90 d
LOVIS-2
(NCT00822666)
PI: J.-P. Collet
PI: G. Montalescot
Randomized, open-label,
phase III, crossover
(PD/PK study)
120 Post-MI,
45 y and
enrolled in AFIJI
registry
Comparison of 2 loading
strategies of clopidogrel (300
mg vs. 900 mg) in 2 genetic
profiles: wild-type 2C19*1 and
carriers of
2C19*2 (homozygous or
heterozygous)
Inhibition of RPA (IRPA)
by optical
aggregometry;
measurement of
active metabolites
6 h postclopidogrel
loading dose
ole of CYP2C19
Polymorphism in
the Drug Interaction
Between
Clopidogrel and
Omeprazole
(NCT01094275)
PI: S. Nadipalli
PI: T. Delao
Observational, case-
crossover, phase IV
(PD/PK study)
75 Healthy volunteers Subjects with CYP2C19*2/*3
LOF allele, and age- and
gender-matched wild-type
control randomized to
clopidogrel  omeprazole vs.
clopidogrel  1 wk, and
crossover
Platelet inhibitory
response to
clopidogrel;
measurement of
active metabolites
3 wk
LEVATE-TIMI 56
PI: J.L. Mega (58a)
Randomized treatment
sequence
(PD study)
275 Stable CAD Patients on clopidogrel 75 mg
and genotyped for CYP2C19
alleles will be treated with
biweekly dose of clopidogrel
“(75 mg to 300 mg daily,
depending on genotype).”
Change in RPA
(VerifyNow, VASP)
8 wk
REDICT Pilot Study
(NCT00747656)
PI: M.J. Price
Observational prospective
cohort
(PD study)
42 Stable CAD on
clopidogrel
therapy
Patients with HRPA on
clopidogrel 75 mg and
genotyped for CYP2C19
alleles treated with double-
dose clopidogrel
(150 mg)
Change in RPA
(VerifyNow)
7 d
CCEL-2C19
(NCT01012193)
PI: Y.-H. Jeong
Randomized, active-
control, single-blind
(PD study)
134 Stable CAD,
elective PCI
Patients genotyped for CYP2C19
variants randomized to high-
dose clopidogrel (150 mg) 
ASA 200 mg vs. cilostazol
100 mg bid  75 mg
clopidogrel  ASA 200 mg
(triple therapy)
Inhibition of maximum
platelet aggregation
(optical
aggregometry;
VerifyNow)
30 d
CCELAMI2C19
(NCT00915733)
PI: I.-S. Kim
Randomized, active-
control, open-label
(PD study)
80 Acute MI,
post-PCI
Patients genotyped for CYP2C19
variants randomized to high-
dose clopidogrel (150 mg) 
ASA 100 mg vs. cilostazol
100 mg bid  75 mg
clopidogrel  ASA 100 mg
(triple therapy)
Inhibition of maximum
platelet aggregation
(optical
aggregometry;
VerifyNow)
30 d
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July 20, 2010:321–41 ACCF/AHA Clopidogrel Clinical Alertonventional, unmonitored strategy. The primary outcome in
hese trials is the time to first occurrence of cardiovascular
omplications including cardiovascular death, nonfatal MI,
onfatal stroke, stent thrombosis, or target vessel revascular-
zation at 6 or 12 months. The routine clinical use of platelet
unction testing to screen clopidogrel-treated patients under-
oing PCI in order to maximize efficacy while maintaining
afety may be supported only after these clinical trials are
ompleted.
Pharmacogenetic and/or PD profiling could potentially
ffer a tool to identify a priori patients in whom an
lternative antiplatelet approach to standard-dose clopi-
ogrel would decrease ischemic events. Options include
cute administration of glycoprotein IIb/IIIa inhibitors or
onger-term use of higher-dose clopidogrel, cilastozol, pra-
ugrel, ticagrelor, or new agents such as elinogrel (26).
lthough the effectiveness of ticagrelor in improving car-
iovascular outcomes was demonstrated in the PLATO
Platelet Inhibition And Patient Outcomes) trial, this drug
s not approved by the FDA. Another promising drug,
linogrel, has only been evaluated in a phase 2 study. At the
able 4. Continued
Study Design
No. of
Patients Population
CCEL-2C19
(NCT00891670)
PI: Y.-H. Jeong
Randomized, active-
control, open-label
(PD study)
80 Stable CAD,
Elective PCI
PICE
(NCT00930670)
PI: U. Dery
PI: G. Rossignol
Randomized, active-
control, open-label
(PD study)
320 Stable CAD,
elective PCI
BMS
nfluence of CYP2C19
Genetic Variants on
Clopidogrel in
Healthy Subjects
(NCT00413608)
PI: J.S. Hulot
Observational, active-
control, open-label
(PD/PK study)
30 Healthy volunt
Trials Evaluatin
eCCO
(NCT00995514)
PI: E.J. Stanek
Observational, prospective
cohort, open-label,
active control,
noninferiority study
(outcome study)
14 600 Recent NSTEM
STEMI ACS
or without
primary or
delayed PCI
CCEL-2C19, Adjunctive Cilostazol Versus High Maintenance-dose Clopidogrel According to Cy
lopidogrEL in Acute Myocardial Infarction (AMI) Patients According to CYP2C19 Polymorphism;
ggressive Intervention; ASA, acetylsalicylic acid; BMS, bare-metal stent; CAD, coronary artery d
ytochrome P450; DES, drug-eluting stent; GeCCO, Genotype Guided Comparison of Clopidogre
auging Responsiveness With A VerifyNow Assay-Impact On Thrombosis And Safety; HRPA, hig
levation myocardial infarction; PCI, percutaneous coronary intervention; PD, pharmacodynam
valuation and Economic Analysis of Different Coronary Syndrome Treatment Strategies; RPA,
lopidogrel Antiplatelet Effects; STEMI, ST-segment elevation myocardial infarction; TVR, target-resent time, prasugrel is the only new agent approved to iupport PCI in patients with ACS. It must be kept in mind,
owever, that the use of prasugrel in high-risk genotype
atients after elective PCI has not been studied. With
egard to clopidogrel dose adjustment in patients with high
latelet reactivity on standard clopidogrel treatment, the
esults are mixed. Two studies yielded improved outcomes
f major adverse cardiovascular events or stent thrombosis
ith this approach (59,60). In contrast, 1 case series of
atients with prior MI who subsequently developed stent
hrombosis questioned the strategy of increasing clopidogrel
ose in carriers of CYP2C19*2 as time-consuming and
argely ineffective at providing adequate platelet inhibition
although prasugrel was able to suppress platelet aggregation
uccessfully) (61). Even if the relationship between genetic
olymorphisms and ischemic risk is well established, the
ffect on bleeding remains to be elucidated. It is possible
hat the relationship between genetic polymorphisms and
ntiplatelet effect is somewhat different for thrombosis and
leeding. Higher levels of active-metabolite generation may
ot necessarily translate into an optimal benefit-risk bal-
nce. As documented in the preceding text, it is difficult to
Selection Criterion Outcome Follow-Up
Patients genotyped for CYP2C19
variants randomized to high-
dose clopidogrel (150 mg) 
ASA 100 mg vs. cilostazol
100 mg bid  75 mg
clopidogrel  ASA 100 mg
(triple therapy)
Maximum platelet
aggregation
(optical
aggregometry;
VerifyNow)
30 d
Subjects genotyped for CYP2C19
alleles and treated with
clopidogrel randomized to
statin  PPI or statin  H2RA
Change in RPA
(optical
aggregometry; VASP)
Death, MI, stroke, or
ischemia-driven TVR
(secondary end point)
30 and 60 d
Patients genotyped for CYP2C19
variants with HRPA on
clopidogrel 75 mg (“bad
responders”) will be given 150
mg clopidogrel and compared
with results of 75 mg
clopidogrel in “good
responders”
Change in RPA
(optical
aggregometry);
measurement of
active metabolites
7 d
ical Outcomes
Genotype-guided comparison of
clopidogrel (75mg daily) in
extensive metabolizers
(CYP2C19*1/*1) and
prasugrel (5 mg or 10 mg
daily)
CV death, nonfatal MI,
or nonfatal stroke
6 mo
e 2C19 Polymorphism; ACCELAMI2C19, Adjunctive Cilostazol Versus High Maintenance-dose
cute coronary syndromes; AFIJI, Appraisal of Risk Factors in Young Ischemic Patients Justifying
CLOVIS-2, Clopidogrel and Response Variability Investigation Study 2; CV, cardiovascular; CYP,
asugrel Outcomes Study; GIFT, Genotype Information and Functional Testing Study; GRAVITAS,
ual platelet activity; LOF, loss-of-function; MI, myocardial infarction; NSTEMI, non–ST-segment
primary investigator; PK, pharmacokinetic; PPI, proton pump inhibitor; PREDICT, Prehospital
l platelet activity; SPICE, Evaluation of the Influence of Statins and Proton Pump Inhibitors on
revascularization; and VASP, vasodilator-stimulated phosphoprotein phopsphorylation.with
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tochrom
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btained in patient subsets. A fundamental issue remains
hat it is not known whether treatment decisions predicated
n the results of either genotyping or phenotyping infor-
ation can impact optimization of either clinical efficacy
nd/or safety. Genotyping of patients enrolled in the studies
isted in Table 4, and the ONSET/OFFSET (Randomized
ouble-Blind Assessment of the ONSET and OFFSET of
he Antiplatelet Effects of Ticagrelor Versus Clopidogrel in
atients With Stable Coronary Artery Disease) study (62),
hich demonstrated superior antiplatelet effects of ticagre-
or compared with higher LD of clopidogrel, or the
ESPOND (Response to Ticagrelor in Clopidogrel Non-
esponders and Responders and Effect of Switching Ther-
pies) study (58), which showed similar platelet inhibitory
ffects of ticagrelor in clopidogrel responders and nonre-
ponders alike, will likely yield valuable insights in this
egard.
In summary, larger and longer-term prospective studies
hat include cardiovascular event outcomes are necessary to
ptimize predictive algorithms that may include genetic
nd/or platelet function testing, and their use to individu-
lize P2Y12 inhibitor therapy. However, it is important to
ecall that CYP2C19 polymorphism accounts for only
pproximately 12% of variability in clopidogrel platelet
esponse (15) and that the positive predictive value of
YP2C19 loss-of-function genetic polymorphisms for clin-
cal events is estimated to be between 12% (16) and 20% (2)
able 5. Trials Evaluating Antiplatelet Therapy Tailored by Pha
Study Design
No. of
Patients Population
RAVITAS
(NCT00645918)
PI: M.J. Price
Randomized,
placebo-control,
multicenter
2800 Stable CAD or
NSTEMI ACS
undergoing
PCI (DES)
RCTIC
(NCT00827411)
PI: G. Montalescot
PI: J.-P. Collet
Randomized,
active-controlled,
open label,
phase IV,
multicenter
2500 Stable CAD,
elective PCI
RIGGER-PCI
(NCT00910299)
Sponsor: Eli Lilly
Randomized,
active-control,
double blind,
phase II,
multicenter
2150 Stable CAD,
elective PCI
ANTE
(NCT00774475)
PI: G.F. Gensini
PI: R. Marcucci
Randomized,
active-control,
open-label,
phase III,
multicenter
442 NSTEMI ACS
undergoing
PCI
CS indicates acute coronary syndromes; ARCTIC, Double Randomization of a Monitoring Adj
nterruption Versus Continuation of Double Antiplatelet Therapy; CAD, coronary artery disease; C
rug-eluting stent; GRAVITAS, Gauging Responsiveness With A VerifyNow Assay-Impact On
on–ST-segment elevation myocardial infarction; PCI, percutaneous coronary intervention; PI,
lacement on Clopidogrel to Guide Alternative Therapy With Prasugrel; and TVR, target-vessel ren patients with ACS undergoing PCI. Even if slightly aetter than the positive predictive values observed with the
oint-of-care P2Y12 assay in a similar population (12%)
63–65), the predictive accuracy of these genetic polymor-
hisms is still low. Thus, improvement in prediction of
uture cardiovascular events in patients receiving antiplatelet
herapy will likely benefit from development of a global risk
ssessment score based on traditional demographic, clinical,
nd procedural risk factors, genetics, and biological infor-
ation rather than any single test result.
. Conclusions
.1. Issues for Consideration
he information on the pharmacogenomics that has formed
he basis for the recent boxed warning on clopidogrel is of
reat importance in understanding the issues related to
ariability in clinical outcomes of patients with both acute
nd chronic coronary artery disease; in addition, this infor-
ation may have applicability for patients with stroke and
eripheral arterial disease, although there are no robust data
n these populations. There are several critical issues that
equire careful consideration. As noted in the preceding
ext, CYP2C19 polymorphism accounts for only approxi-
ately 12% of variability in clopidogrel platelet response,
nd the positive predictive value of CYP2C19 loss-of-
unction genetic polymorphisms is estimated to be between
2% and 20% in patients with ACS undergoing PCI. In
odynamic Assessment
Selection Criterion Outcome Follow-Up
tients with HRPA 12- to 24-h
post-DES randomized to: 1)
standard 75 mg clopidogrel; or
2) high-dose clopidogrel
(additional 600 mg followed by
150 mg daily)
CV death, nonfatal MI, or
definite/probable
stent thrombosis
6 mo
tients post-DES randomized to:
1) standard dose clopidogrel
plus aspirin (conventional arm);
or 2) adjusted-dose clopidogrel
plus aspirin based on HRPA
(monitoring arm)
Death, nonfatal MI,
stroke, urgent TVR, or
stent thrombosis
1 y
tients 24 h post-DES and
2 to 7 h postclopidogrel and
HRPA randomized to: 1)
prasugrel 60 mg load/10 mg
daily; or 2) clopidogrel 75 mg
daily
CV death or nonfatal MI 6 mo
tients with HRPA randomized to:
1) clopidogrel 75 mg
maintenance (standard dose); or
2) clopidogrel 150 mg
maintenance (high dose)
CV death, nonfatal MI, or
TVR
6 and 12
mo
ntiplatelet Treatment Versus a Common Antiplatelet Treatment for DES Implantation, and a
iovascular; DANTE, Dual Antiplatelet Therapy Tailored on the Extent of Platelet Inhibition; DES,
osis And Safety; HRPA, high residual platelet activity; MI, myocardial infarction; NSTEMI,
y investigator; TRIGGER-PCI, Testing Platelet Reactivity In Patients Undergoing Elective Stent
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hisms cannot be excluded, and there is a larger body of
vidence to support platelet function testing as a risk
tratifier for adverse events. These issues must be considered
n the context that there are multiple unknown factors
ncluding, most importantly, the fact that the specific role of
n individual genetic polymorphism in influencing outcome
or the individual patient remains unknown.
. Guideline adherence remains the cornerstone of care.
Clinical judgment is required to assess individual risk and
variability in response to clopidogrel. While imperfect,
such judgment is essential. In addition to consideration
of evidence-based guidelines, it is crucial to emphasize
patient compliance with the prescribed antiplatelet reg-
imen. Given the large interindividual variability in re-
sponse to clopidogrel resulting from both clinical and
genetic factors, the issues of genotyping and measure-
ment of platelet inhibition have been raised, particularly
in patients felt to be at highest risk for adverse events and
in patients who have already had an adverse event despite
compliance with regimens of aspirin and clopidogrel
(coronary artery disease patients) or clopidogrel mono-
therapy (cerebrovascular ischemia patients).
. Information on patients at risk for poor outcomes with
ACCF/AHA and AHA Stroke Council Guideline-
recommended therapy continues to accumulate. Some
patients are identified because they have experienced an
adverse outcome, such as stent thrombosis, while other
patients may be considered to be at increased risk of a
subsequent adverse outcome, including stent thrombosis,
MI, ischemic stroke, and vascular death. This latter
consideration may be based on clinical characteristics
such as diabetes mellitus, chronic renal failure, or angio-
graphic variables (e.g., diffuse 3-vessel or left-main cor-
onary artery disease or multifocal cervicocerebral athero-
sclerotic disease). In the future, profiling high-risk
populations may include consideration of the frequency
of the genetic penetration of genetic polymorphisms in
that specific population.
. Genetic variability in CYP enzymes may affect platelet
function and has been associated with adverse patient
outcomes in registry experiences and clinical trials. Al-
though CYP2C19*2 is the most common genetic variant
reproducibly associated with impaired responses to clo-
pidogrel, the specific role of the individual genetic
polymorphisms in impacting outcome remains to be
determined (e.g., the importance of CYP2C19*2 versus
*3 or *4 for a specific patient). In addition, there are other
genetic polymorphisms such as ABCB1 that may also
contribute to variation in the response of individual
patients to clopidogrel.
Information about the predictive value of pharmacog-
enomic testing is very limited, but is the focus of multiple
ongoing studies. The design of such studies in terms of
specific tests and patient populations (e.g., acute careversus chronic care settings) will have major implications
for the role of testing. A related issue is whether the risk
from a given individual’s genomic profile changes over
time, depending on the specific clinical scenario (e.g.,
ACS versus stable angina pectoris, PCI versus medical
therapy, small vessel versus large artery, atherosclerotic
ischemic stroke, or carotid stenting versus medical ther-
apy), is relevant. This question has yet to be resolved.
. The answer to the specific question of the role of
genotyping in everyday practice remains unknown at the
present time. Although the boxed warning does not
mandate testing, proponents would argue that there are
common genetic polymorphisms that have been shown
to affect the platelet response to clopidogrel as well as its
clinical effectiveness in both randomized clinical trials
and registry experiences. In addition, there are commer-
cially available genetic tests that can determine
CYP2C19 genotype variants although the turn-around
time varies as does the cost, which is not routinely
reimbursable at this time. Advocates argue that given the
magnitude of the potential clinical consequences of
suboptimal platelet inhibition based on genetic variation,
assessment of genotypes would be justifiable. In contrast,
opponents believe that there is no definitive proof at the
current time that intervening on the basis of genotype
improves outcome, and that there are other factors that
may be more important. In addition, they would raise the
question of whether genotyping should be confined to
loss-of-function CYP2C19*2 or *3 (poor metabolizers),
or be extended to other variants including the gain-of-
function CYP2C19*17 variant (hyper-rapid or ultrarapid
metabolizers). As part of this argument, opponents note
that the predictive performance of CYP2C19 variant is
low, ranging from 12% to 20%, and raise the question of
what to do when variant genotype information is iden-
tified in patients with no clinical events. Finally, they
would note that there are no point-of-care genotyping
tests, which severely limits the usefulness of these data in
the acute care setting. Currently, there are studies un-
derway or in the planning stages that will address these
issues to varying degrees. Despite the gaps in current
knowledge, both clinicians and patients need to be aware
of genetic polymorphisms that may modulate clopidogrel
responsiveness and cause MACE. It is important to
emphasize again that in the most recent labeling for
clopidogrel, the FDA only informs physicians and pa-
tients that genetic testing is available; it neither man-
dates, requires, nor recommends genetic testing, thereby
allowing for flexibility in clinical decisions.
. Given the concerns about the mortality and morbidity
that may be attributable to an inadequate response to
antiplatelet therapy, there are a number of alternative
approaches to standard guideline-based care with clopi-
dogrel. New agents and new strategies have been used
clinically and tested in a wide variety of situations. New
agents such as prasugrel and ticagrelor, which are not
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to be more effective than standard-dose clopidogrel. This
relates to the PK characteristics of these newer agents. In
very high-risk clinical circumstances (e.g., prior stent
thrombosis) such agents may be considered alternatives
to standard ACCF/AHA and AHA Stroke Council
Guideline therapy. This is particularly important in any
patient suspected of treatment failure to standard-dose
clopidogrel. Other treatment strategies are also being
tested, including increased clopidogrel dosing or the
addition of a third drug such as cilostazol to aspirin and
clopidogrel. In the setting of stroke or transient ischemic
neurologic symptoms, the combination of aspirin and
extended release dipyridamole and aspirin monotherapy
are alternatives recommended by the AHA Stroke Council
guidelines for secondary prevention of stroke (66).
.2. Recommendations for Practice
onsideration of these critical issues leads to the following
ecommendations for clinicians:
. Adherence to existing ACCF/AHA guidelines for the
use of antiplatelet therapy should remain the foundation
for therapy. Careful clinical judgment is required to
assess the importance of the variability in response to
clopidogrel for an individual patient and its associated
risk to the patient. While imperfect, such careful judg-
ment is essential.
. Clinicians must be aware that genetic variability in CYP
enzymes alter clopidogrel metabolism, which in turn can
affect its inhibition of platelet function. Diminished
responsiveness to clopidogrel has been associated with
adverse patient outcomes in registry experiences and
clinical trials.
. The specific impact of the individual genetic polymor-
phisms on clinical outcome remains to be determined
(e.g., the importance of CYP2C19*2 versus *3 or *4 for
a specific patient), and the frequency of genetic variabil-
ity differs among ethnic groups. This has particular
relevance related to the frequency of homozygotes, which
occurs in approximately 2% of the population, versus
heterozygotes, which occurs in approximately 30% of the
population, both of whom may have increased risk.
. Information regarding the predictive value of pharma-
cogenomic testing is very limited at this time; resolu-
tion of this issue is the focus of multiple ongoing
studies. The selection of the specific test, as well as the
issue of reimbursement, are both important additional
considerations.
. The evidence base is insufficient to recommend either
routine genetic or platelet function testing at the present
time. There is no information that routine testing
improves outcome in large subgroups of patients. In
addition, the clinical course of the majority of patients
treated with clopidogrel without either genetic testing or
functional testing is excellent. Clinical judgment is re-quired to assess clinical risk and variability in patients
considered to be at increased risk. Genetic testing to
determine if a patient is predisposed to poor clopidogrel
metabolism (“poor metabolizers”) may be considered
before starting clopidogrel therapy in patients believed to
be at moderate or high risk for poor outcomes. This
might include, among others, patients undergoing elec-
tive high-risk PCI procedures (e.g., treatment of exten-
sive and/or very complex disease). If such testing iden-
tifies a potential poor metabolizer, other therapies,
particularly prasugrel for coronary patients, should be
considered. With these other therapies, the balance of
potential ischemic benefit with the known increased risk
of bleeding should be considered either with alternative
clopidogrel dosing or newer agents such as prasugrel. In
particular, prasugrel is contraindicated in patients with
stroke and TIA. For patients with ischemic stroke or
TIA, alternatives to clopidogrel include aspirin or the
combination of aspirin and extended-release dipyridam-
ole, which are both recommended in the AHA Stroke
Council guidelines for secondary prevention of stroke (66).
. There are several possible therapeutic options for pa-
tients who experience an adverse event while taking
clopidogrel in the absence of any concern about medi-
cation compliance. Clopidogrel may be switched to
prasugrel, which has been found to result in decreased
rates of stent thrombosis, and as noted previously,
prasugrel is contraindicated for patients with stroke or
TIA in patients treated with PCI for ACS, although it
has not been tested in randomized trials of patients with
stent thrombosis. Alternatively, the physician may make
the empiric recommendation to increase the dose of
clopidogrel (e.g., to 150 mg per day). There are very little
data to judge the trade-off of high-dose clopidogrel
versus alternative therapies on the risk-benefit ratio of
safety (avoidance of bleeding) versus efficacy (prevention
of a second recurrence). Functional testing may be
performed and may be considered in an attempt to
determine if patients are clopidogrel nonresponders.
There are several different platelet function tests that can
be used to assess the platelet response to clopidogrel, and
the clinician should use the method with the greatest
reliability and reproducibility at his or her specific facil-
ity. For stroke patients, aspirin or the combination of
aspirin and extended-release dipyridamole are alterna-
tives, as noted in the preceding text.
. Higher LDs (600 mg versus 300 mg), double-dose
loading (600 mg twice over 2 hours), and higher MDs of
clopidogrel (150 mg daily) have been found to improve
platelet inhibition and might be considered alternatives
for high-risk patients who respond poorly to standard
loading and MDs of clopidogrel, although there is
uncertainty of the long-term safety and efficacy of this
approach. New antiplatelet drugs such as prasugrel and,
if FDA approved, ticagrelor are additional alternatives in
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July 20, 2010:321–41 ACCF/AHA Clopidogrel Clinical Alertcoronary patients with a known poor response to clopi-
dogrel or in patients at high risk for a poor outcome from
potential clopidogrel nonresponsiveness. Their use may
obviate the need for additional testing. Other possibili-
ties are adding cilostazol to standard doses of aspirin and
clopidogrel (67) or using cilostazol alone (68–70). How-
ever, because platelet inhibition still may not be optimal
with these regimens, follow-up platelet function testing
might be considered to ensure adequate platelet inhibition.
The risk-benefit ratio, in terms of safety and efficacy of each
of these alternative strategies, remains to be determined by
adequately powered clinical trials.
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afety Announcement
03-12-2010] The U.S. Food and Drug Administration
FDA) has added a Boxed Warning to [sanofi-aventis,
ridgewater, NJ] for Plavix, the antiblood clotting medica-
ion. The Boxed Warning is about patients who do not
ffectively metabolize the drug (i.e., “poor metabolizers”)
nd therefore may not receive the full benefits of the drug.
The Boxed Warning in the drug label will include infor-
ation to:
• Warn about reduced effectiveness in patients who
are poor metabolizers of Plavix. Poor metabolizers
do not effectively convert Plavix to its active form in
the body.
• Inform healthcare professionals that tests are available
to identify genetic differences in CYP2C19 function.
• Advise healthcare professionals to consider use of
other antiplatelet medications or alternative dosing
strategies for Plavix in patients identified as poor
metabolizers.
Plavix is given to reduce the risk of heart attack, unstable
ngina, stroke, and cardiovascular death in patients with
ardiovascular disease. Plavix works by decreasing the activ-
ty of blood cells called platelets, making platelets less likely
o form blood clots.
For Plavix to work, enzymes in the liver (particularly
YP2C19) must convert (metabolize) the drug to its active
orm. Patients who are poor metabolizers of the drug do not
ffectively convert Plavix to its active form. In these patients,
lavix has less effect on platelets, and therefore less ability to
revent heart attack, stroke, and cardiovascular death. It is
stimated that 2% to 14% of the population are poor
etabolizers; the rate varies based on racial background.
Healthcare professionals should be aware that a sub-
roup of patients are poor metabolizers and do not metab-
lize Plavix effectively; this can result in reduced effective-
ess of Plavix. Healthcare professionals should consider use
f other antiplatelet medications or alternative dosing strat-
gies for Plavix in these patients.
Patients should not stop taking Plavix unless told to do
o by their healthcare professional. They should talk with
heir healthcare professional if they have any concerns about
lavix, or to find out if they should be tested for being a
oor metabolizer.
In May 2009, the FDA added information about poor
etabolizers of Plavix to the drug label. However, based on
dditional data reviewed by the agency (see Data Summary
n the following text), the Boxed Warning is now being
dded to highlight the reduced effectiveness of Plavix in
hese patients and to recommend that healthcare profes-
ionals consider use of other antiplatelet medications orlternative dosing strategies for Plavix in patients identified
s poor metabolizers.
dditional Information for Patients
atients currently taking Plavix should:
• Be aware that some patients do not convert Plavix to
its active form as well as other patients. These patients
may not get the same benefit from Plavix and are
known as poor metabolizers.
• Do not stop taking Plavix unless told to do so by their
healthcare professional.
• Talk with their healthcare professional if they have any
concerns about Plavix.
• Talk with their healthcare professional to see if testing
to determine their metabolizer status is appropriate.
dditional Information for Healthcare Professionals
he FDA recommends that healthcare professionals
hould:
• Be aware that some patients may be poor metabolizers
of Plavix. They do not effectively convert Plavix to its
active form because of low CYP 2C19 activity. The
effectiveness of Plavix as a preventive therapy is re-
duced in these patients.
• Be aware that tests are available to determine patients
CYP2C19 status.
• Consider use of other antiplatelet medications or
alternative dosing strategies for Plavix in patients who
have been identified as poor metabolizers.
• Be aware that although a higher dose regimen (600 mg
loading dose followed by 150 mg once daily) in poor
metabolizers increases antiplatelet response, an appro-
priate dose regimen for poor metabolizers has not been
established in a clinical outcome trial.
• Review the newly approved Plavix drug label for
complete information on the use of Plavix
ata Summary
he liver enzyme CYP2C19 is primarily responsible for the
ormation of the active metabolite of Plavix. Pharmacoki-
etic and antiplatelet tests of the active metabolite of Plavix
how that the drug levels and antiplatelet effects differ
epending on the genotype of the CYP2C19 enzyme. The
ollowing represent the different alleles of CYP2C19 that
ake up a patient’s genotype:
• The CYP2C191 allele has fully functional metabo-
lism of Plavix.
• The CYP2C192 and 3 alleles have no functional
metabolism of Plavix. These 2 alleles account for most
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pean] (85%) and Asian (99%) descent classified as poor
metabolizers.
• The CYP2C194, 5, 6, 7, and 8 and other alleles
may be associated with absent or reduced metabolism
of Plavix, but are less frequent than the CYP2C192
and 3 alleles.
• A patient with 2 loss-of-function alleles (as defined in
the preceding text) will have poor metabolizer status.
The pharmacokinetic and antiplatelet responses to Plavix
ere evaluated in a crossover trial in 40 healthy subjects.
en subjects in each of the 4 CYP2C19 metabolizer groups
ultrarapid, extensive, intermediate, and poor) were ran-
omized to 2 treatment regimens: a 300 mg loading dose
ollowed by 75 mg per day, or a 600 mg loading dose
ollowed by 150 mg per day, each for a total of 5 days. After
washout period, subjects were crossed over to the alternate
reatment. Decreased active metabolite exposure and in-
reased platelet aggregation were observed in the poor
etabolizers compared with that seen in the other groups.
hen poor metabolizers received the 600 mg loading dose
ollowed by 150 mg daily, active metabolite exposure and
ntiplatelet response were greater than with the 300 mg/75
g regimen. Healthcare professionals should note that an
ppropriate dose regimen for patients who are poor metabo-
izers has not been established in clinical outcome trials (1).ore Information
elated Information
• FDA Drug Safety Communication: Reduced effec-
tiveness of Plavix (clopidogrel) in patients who are
poor metabolizers of the drug. Release date: 3/12/2010
• Public Health Advisory: Updated Safety Information
about a drug interaction between clopidogrel bisulfate
(marketed as Plavix) and omeprazole (marketed as
Prilosec and Prilosec OTC). Release date: 11/17/2009
• Information for Healthcare Professionals: Update to
the labeling of Clopidogrel Bisulfate (marketed as
Plavix) to alert healthcare professionals about a drug
interaction with omeprazole (marketed as Prilosec and
Prilosec OTC). Release date: 11/17/2009
• Follow-Up to the January 26, 2009, Early Communi-
cation about an Ongoing Safety Review of Clopidogrel
Bisulfate (marketed as Plavix) and Omeprazole (mar-
keted as Prilosec and Prilosec OTC). Release date:
11/17/2009
• Early Communication about an Ongoing Safety Re-
view of clopidogrel bisulfate (marketed as Plavix).
Release date: 1/26/2009
• Clopidogrel (marketed as Plavix) and Omeprazole
(marketed as Prilosec)–Drug Interaction. Release date:
11/17/2009
